Mark Smith
47Patents
11h-index
58Co-inventors
78Inventor score
Filing activity: Dec 17, 1999 → Sep 30, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7541444B2 | Modified nucleotides | Emerging Cross-Sectional Technologies | 207 | Expired |
| US6846810B2 | Antiviral nucleoside derivatives | Human Necessities | 118 | Expired |
| US9889422B2 | Methods of localizing nucleic acids to arrays | Emerging Cross-Sectional Technologies | 85 | Active |
| US7771973B2 | Modified nucleotides | Emerging Cross-Sectional Technologies | 80 | Active |
| US8071739B2 | Modified nucleotides | Emerging Cross-Sectional Technologies | 59 | Active |
| US8563477B2 | Modified molecular arrays | Emerging Cross-Sectional Technologies | 53 | Active |
| US8597881B2 | Modified nucleotides | Emerging Cross-Sectional Technologies | 46 | Active |
| US9121060B2 | Modified nucleotides | Emerging Cross-Sectional Technologies | 40 | Active |
| US7378402B2 | Anti-viral nucleosides | Chemistry; Metallurgy | 38 | Expired |
| US9388464B2 | Modified nucleotides | Emerging Cross-Sectional Technologies | 35 | Active |
| US6458851B1 | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications | Human Necessities | 13 | Expired |
| US10513731B2 | Modified nucleotides | Emerging Cross-Sectional Technologies | 11 | Active |
| US8969258B2 | Methods of localizing nucleic acids to arrays | Emerging Cross-Sectional Technologies | 8 | Active |
| US9295729B2 | Reversible covalent linkage of functional molecules | Emerging Cross-Sectional Technologies | 7 | Active |
| US10525437B2 | Methods and compositions of localizing nucleic acids to arrays | Emerging Cross-Sectional Technologies | 5 | Active |
| US9376710B2 | Methods of localizing nucleic acids to arrays | Emerging Cross-Sectional Technologies | 4 | Active |
| US9926309B2 | Pi-kinase inhibitors with anti-infective activity | Chemistry; Metallurgy | 4 | Active |
| US6462091B1 | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications | Human Necessities | 4 | Expired |
| US9370569B2 | 4′-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication | Chemistry; Metallurgy | 4 | Active |
| US11654411B2 | Methods and compositions of localizing nucleic acids to arrays | Emerging Cross-Sectional Technologies | 3 | Active |
| US10092649B2 | 4′-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication | Chemistry; Metallurgy | 3 | Active |
| US10953379B2 | Methods and compositions of localizing nucleic acids to arrays | Emerging Cross-Sectional Technologies | 3 | Active |
| US9895442B2 | 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication | Chemistry; Metallurgy | 2 | Active |
| US8921388B2 | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | Chemistry; Metallurgy | 2 | Active |
| US11091472B2 | PI-kinase inhibitors with anti-infective activity | Chemistry; Metallurgy | 2 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.